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Introduction
Without a new medication approved for systemic lupus
erythematosus (SLE) by the Food and Drug Administration
in more than 40 years, there has been a recent flurry of
research activity and clinical trials. However, a basic epi-
demiologic understanding of SLE, which is necessary to
understand the full clinical spectrum and population bur-
den, lags behind. Estimates of the incidence and preva-
lence of SLE in the US have varied widely and are out-
dated (Table 1). This is likely due to the use of different
case definitions, limited sources for case ascertainment,
small source populations, and different demographic
groups targeted, as well as the protean characteristics of
the disease, poor reliability of self-report, lack of reliability
in diagnosis and coding in health system databases, and
issues related to access to health care by high-risk popu-
lations. Estimates for other types of lupus (e.g., primary
discoid lupus) are even less well defined.
Two ongoing population-based lupus registries are cur-
rently addressing many of these issues, using methods that
take advantage of novel federal, state, and local partner-
ships. In keeping with the goals of the “National Arthritis
Action Plan: A Public Health Strategy” (1), the Centers for
Disease Control and Prevention (CDC) Arthritis Program in
2002 competitively funded small grants in the health de-
partments of 3 states to plan a population-based registry to
better define the incidence and prevalence of diagnosed
lupus and to better characterize individuals with this dis-
ease. Areas with a population of more than 1 million and
with a relatively large African American proportion were
eligible. In 2003, state health departments in Georgia and
Michigan along with their academic partners, Emory Uni-
versity and the University of Michigan, were competi-
tively awarded funding to perform this research.
This article provides an overview of the methods used in
these registries, focusing primarily on SLE and emphasiz-
ing aspects unique in the field of lupus epidemiology. We
also report briefly on our progress and discuss future di-
rections.
Materials and Methods
The primary aim of the Georgia Lupus Registry and the
Michigan Lupus Epidemiology and Surveillance Program
is to determine the prevalence in 2002 and the incidence
in 2002–2004 of diagnosed SLE in defined geographic
areas: Fulton and Dekalb counties (Atlanta) in Georgia,
and Wayne (Detroit) and Washtenaw (Ann Arbor) counties
in Michigan.
Preregistration activities (2003–2004). A fundamental
strategy for the success of the lupus registries is the part-
nership of the state health department with an academic
counterpart. The state health department has the power to
conduct public health surveillance and provides surveil-
lance expertise. Because of its legal authority, the state
health department is a “public health authority” under the
Health Insurance Portability and Accountability Act
(HIPAA) Privacy Rule (45 CFR parts 160 and 164). Health
care providers are allowed under the HIPAA Privacy Rule
to provide protected health information, without written
patient consent, to state health departments and their des-
ignated agents (45 CFR 164.512[b]). Collecting protected
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health information is needed to determine if diagnosed
cases meet case definition criteria and to provide enough
information to prevent duplicate entry of patients, because
the same patient may be encountered in multiple facilities.
Obtaining individual consent for case finding and medical
record reviews would be prohibitively costly and time
consuming, and result in severe underreporting and biased
ascertainment. The academic partner provides the onsite
expertise in lupus to conduct the registry. Therefore, the
state health departments contracted with the academic
partners (Emory University and the University of Michi-
gan) to implement the CDC grant by managing the project
and collecting the data. In addition, all pertinent local,
university, state, and CDC Institutional Review Board re-
views and approvals have been obtained.
Advisory committees comprised of regional leaders
from academia and private practices were established
early at each site to address potential roadblocks and to
help finalize the methods. Representatives from hospital
organizations, medical records departments, and patient




























































































































* SLE  systemic lupus erythematosus; ND  not determined; ANA  antinuclear antibody; LE cell  lupus erythematosus cell; NHANES-III  Third
National Health and Nutrition Examination Survey.
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advocacy groups also participated. Outreach from the ad-
visory committees to relevant specialty organizations and
hospitals helped to maximize awareness and participa-
tion.
With CDC coordination, monthly conference calls, and
consultation by a lupus epidemiology expert (CG) who had
completed a similar population-based study of SLE inci-
dence and prevalence using multiple sources of case as-
certainment in the UK (2), a standard set of methods and
data definitions was developed for both sites. The intent
was to minimize methodologic differences between these
2 registries when comparing estimates, which is a common
problem in comparing lupus estimates between other
studies.
Case finding (registration methods, 2004 to present). To
maximize ascertainment of potential cases, a broad range
of case-finding sources are being used (Figure 1). Within
each source, a search is made for SLE, discoid lupus, and
selected conditions that may evolve into SLE or have re-
lated symptoms. Other lupus-related conditions such as
primary antiphospholipid syndrome, neonatal lupus,
drug-induced lupus, and primary nondiscoid cutaneous
lupus are not being pursued at this time because of their
lack of specific diagnostic codes and/or established classi-
fication criteria. Administrative databases at each source
are queried for the International Classification of Diseases,
Ninth Revision, Clinical Modification billing code 710.0
(SLE), as well as 695.4 (discoid lupus), 710.8 (other spec-
ified connective tissue disease), and 710.9 (unspecified
connective tissue disease). Hospital-based laboratories and
regional pathology laboratories are also queried for results
that may identify patients with SLE or other related con-
ditions (e.g., skin and renal biopsies). Efforts to obtain data
from the larger commercial laboratories and the US Renal
Data System database are currently underway (data have
been obtained from LabCorp; data request is pending for
Quest). Other unique databases such as the Veterans Ad-
ministration data, Medicaid claims data, other state data-
bases (mortality, hospital discharge), and electronic med-
ical record systems are used as available.
Data abstraction. Once a potential case is identified,
only confirmation of residency in a county of interest
during the calendar period of interest is needed to initiate
full abstraction of the various medical records. Abstractors
are thoroughly trained and tested. They do not make an a
priori assessment of the diagnosis, nor do they stop ab-
stracting when any of the classification criteria for SLE
are met. Both sites regularly assess the quality of data
abstraction in a standard fashion by using a method of
re-abstracting medical records. This is a significant im-
provement over previous studies.
Data elements. Personal identifiers are collected to pre-
vent duplicate entry of patients. Detailed addresses are
used to confirm county residency. More than 200 data
elements with detailed definitions in a study glossary are
potentially abstracted for each patient at each facility, with
core data including all of the elements required for various
SLE classification criteria, including the American College
of Rheumatology (ACR) (3) and Boston weighted criteria
(4). For each ACR criterion, the source of the data (reported
by the patient or documented by the physician) and the
earliest date of occurrence are also abstracted. Currently,
the Systemic Lupus International Collaborating Clinics
(SLICC) group is revising the ACR criteria. Each new ele-
ment being evaluated by SLICC not currently in the ACR
criteria was added to the original core data set.
Data analysis. Because abstraction of a potential case is
triggered based on only 2 main criteria (potentially having
SLE and documentation of residency in a county of inter-
est during the calendar period of interest), the registry
databases contain a broad spectrum of patients. Once clas-
sification criteria or other case definitions have been ap-
plied to the broad database, cases can be verified and
demographic and disease subsets identified. Population
denominators were obtained from official government
sources. A capture–recapture analysis with confidence in-
tervals will be performed to estimate the number of cases
missed. Estimates of the incidence and prevalence for
the entire spectrum of diagnosed SLE meeting standard
classification criteria will be obtained using the largest
population-based registries of whites and African Ameri-
cans ever assembled.
Results
A snapshot of the status of abstracting at target facilities
and practices (Table 2) and the numbers of diagnosed SLE
cases meeting classification criteria are reported (Table 3),
stratified by sex and race (African American and white).
Numbers shown are for information only and should not
be used to estimate incidence or prevalence rates.
Figure 1. Sources of potential systemic lupus erythematosus
cases.
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Discussion
Epidemiology is the study of the distribution, determi-
nants, and control of disease in populations. By identify-
ing and counting people with lupus at these sites, more
accurate estimates of incidence and prevalence rates will
greatly improve our understanding of lupus and related
diseases, its public health burden, and implications for
health care planning. The CDC-funded effort to address the
epidemiology of lupus in Georgia and Michigan is the
most comprehensive of such efforts to date in the US. The
size and scope of the active surveillance endeavors cur-
rently underway are designed to encompass the full spec-
trum of lupus, extending beyond the tertiary care setting.
With 3,000 lupus cases already registered, estimates will
be more statistically precise than those previously avail-
able, and meaningful subset analyses will, for the first
time, be feasible from a population-based setting.
Although previous epidemiologic studies of SLE in the
US (Table 1) have all helped to advance our knowledge of
the disease, from an epidemiologic perspective they were
relatively limited because most were not truly population
based or were relatively small in size (range 20–302 cases).
Case ascertainment sources varied considerably, with
some studies only reviewing hospital files, whereas others
used different aspects of electronic records systems and/or
laboratory tests or patient self-report. There was little sys-
tematic review of potential cases outside of hospitals and
rheumatology offices. Classification criteria also varied,
ranging from clinical suspicion with a suggestive histo-
logic or immunologic finding (2) to various versions of the
ACR classification criteria (1971, 1982, or the 1997 update)
(3,5,6). Furthermore, different estimates were adjusted in
different ways or not at all. Consequently, it became diffi-
cult to compare the different studies or to apply any of the
results toward a credible national estimate.
The Georgia Lupus Registry and Michigan Lupus Epide-
miology and Surveillance Program offer several advan-
tages and strengths over previous efforts. They collect
significant clinical information on each patient from a
wide variety of case-finding sources without the limita-
tions of obtaining individual consent, and should provide
population-based estimates of incidence and prevalence
for the full spectrum of diagnosed SLE and primary dis-
coid lupus. Because the classification criteria for SLE may
be in flux, the data elements provide flexibility in adapting
to different case definitions, as well as potentially assess-
ing those criteria. The large number of validated cases
already gathered allows for greater power to look at differ-
ences between sex, race (African Americans versus
whites), and age groups (childhood onset versus adult
onset), and this will improve as case finding and abstract-
ing is completed. Definitions of the core data set and
methods between both states are essentially identical, al-
lowing for comparability between the data sets. The large
size of the registries will provide the best data yet for
estimating the national burden of SLE among whites and
African Americans.
The registries also have limitations. First, the data are
retrospective and abstracted from medical records from
known or suspected lupus patients that were not designed
for epidemiologic purposes. These methods are not de-
signed to capture undiagnosed lupus. Second, the frag-
mented system of health care in the US complicates public
health surveillance efforts. Particularly for complex, non-
communicable diseases such as lupus, some relevant cases
may fail to be captured. To mitigate this risk, we have
designed a comprehensive, active surveillance system
with numerous case-finding sources, and will apply cap-
ture–recapture analysis to estimate the degree of underas-
certainment that may have occurred (7,8). To reduce the
risk of overdiagnosis, detailed quality control measures
have been put in place to ensure that abstractors extract
clinical features that are likely to be due to lupus and not
to another disease process. Third, patients may migrate in
and out of the catchment area for medical care or resi-
dency. Fourth, the methods outlined require significant
effort and expense. Reproduction of such efforts may be
limited by resources. Fifth, these registries do not include
large subsets of other important racial/ethnic populations
Table 3. Current minimum estimates for systemic lupus
erythematosus (SLE) in the ongoing lupus registries (as















African Americans, total 1,046
Men 80
Women 966
* Meeting either 4 of 11 revised 1982 American College of Rheu-
matology (ACR) criteria or 3 ACR criteria with a final diagnosis of
SLE by a rheumatologist.
† Fulton and Dekalb counties.
‡ Wayne and Washtenaw counties.
Table 2. Status of abstracting at case source facilities in
and near the study areas as of December 31, 2008
Facility Total no.
No. completed
or ongoing Complete, %
Georgia
Hospitals 19 17 89
Rheumatologists 34 25 74
Nephrologists 79 38 48
Dermatologists 103 21 20
Michigan
Hospitals 46 20 43
Rheumatologists 67 44 66
Nephrologists 102 56 55
Dermatologists 89 31 35
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thought to potentially be of high risk for SLE in the US,
particularly Hispanics, Asians, and American Indians/
Alaska natives. Planning is currently underway to estab-
lish additional sites in areas that would better capture
these persons and ultimately allow for a more comprehen-
sive and generalizable national estimate to be formulated.
The methods outlined for the 2 registries can potentially
be used for much more than determining incidence and
prevalence of disease. They will allow a cross-sectional
assessment of the association of a variety of factors, includ-
ing socioeconomic factors and outcomes not systemati-
cally incorporated in other epidemiologic studies of lupus.
Once completed, the registries logically will provide a
well-defined cohort that could, with proper consent, be
prospectively followed over time to address important is-
sues with respect to disease progression and management.
The registries in Georgia and Michigan will greatly ad-
vance our epidemiologic knowledge of lupus in the US.
They are a model of how government and academic part-
nerships can be leveraged to effectively ascertain a large
number of cases from multiple sources to obtain reliable
population estimates.
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